Confronting Stage 3 Lung Cancer With Immunotherapy
The U.S. Food and Drug Administration (FDA) recently approved expanding the use of the immunotherapeutic durvalumab (Imfinzi) to include...
Progress Against Cancer
The U.S. Food and Drug Administration (FDA) recently approved expanding the use of the immunotherapeutic durvalumab (Imfinzi) to include...
A new hormone therapy is the first treatment to be approved because it was found to markedly delay the...
The FDA has expanded the use of a molecularly targeted therapeutic to include patients with multiple myeloma. The U.S....
The FDA has approved the molecularly targeted therapeutic olaparib for treating patients who have HER2-negative breast cancer and who...
The FDA has expanded the use of a CD30-targeted antibody?drug conjugate to include two additional types of lymphoma. The...
The newly approved therapeutic is for certain patients with an aggressive type of non-Hodgkin lymphoma called mantle cell lymphoma....
The second of a groundbreaking new type of immunotherapy called CAR T-cell therapy is approved for certain types of...
The FDA has approved a new molecularly targeted therapeutic to treat breast cancer patients with a specific subtype of...
The FDA decision means the immune checkpoint inhibitor nivolumab is now approved for eight types of cancer. Nivolumab (Opdivo)...
The FDA has approved pembrolizumab for treating certain patients with advanced stomach (gastric) cancer. Use of the immunotherapeutic pembrolizumab...